Parkinson disease
R. Balestrino
Department of Neuroscience, University of Turin, Turin, Italy
Search for more papers by this authorCorresponding Author
A.H.V. Schapira
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
Correspondence: Anthony H.V. Schapira, Department of Clinical and Movement Neurosciences, UCL, Queen Square Institute of Neurology, UCL Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. (tel: +44 020 7830 2012; fax: +44 020 7472 6829; e-mail: [email protected]).
Search for more papers by this authorR. Balestrino
Department of Neuroscience, University of Turin, Turin, Italy
Search for more papers by this authorCorresponding Author
A.H.V. Schapira
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
Correspondence: Anthony H.V. Schapira, Department of Clinical and Movement Neurosciences, UCL, Queen Square Institute of Neurology, UCL Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. (tel: +44 020 7830 2012; fax: +44 020 7472 6829; e-mail: [email protected]).
Search for more papers by this authorAbstract
Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 and 11–19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%–15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non-motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α-synuclein, which is found in intra-cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist.
Disclosure of conflicts of interest
Roberta Balestrino: None. Anthony H.V. Schapira: editor-in-chief, European Journal of Neurology.
References
- 1de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology 1997; 48: 1277–81.
- 2Lee A, Gilbert RM. Epidemiology of Parkinson disease. Neurol Clin 2016; 34: 955–65.
- 3von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol J 2005; 15: 473–90.
- 4Gillies GE, Pienaar IS, Vohra S, et al. Sex differences in Parkinson’s disease. Front Neuroendocrinol 2014; 35: 370–84.
- 5Breckenridge CB, Berry C, Chang ET, et al. Association between Parkinson’s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis. PLoS One 2016; 11: e0151841.
- 6Langston JW, Ballard P, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–80.
- 7Angibaud G, Gaultier C, Rascol O. Atypical parkinsonism and Annonaceae consumption in New Caledonia. Mov Disord 2004; 19: 603–4.
- 8Höglinger GU, Michel PP, Champy P, et al. Experimental evidence for a toxic etiology of tropical parkinsonism. Mov Disord 2005; 20: 118–9.
- 9Mittal S, Bjørnevik K, Im DS, et al. β2-adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science 2017; 357: 891–8.
- 10Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson’s disease in a large cohort of men and women. Mov Disord 2012; 27: 1276–82.
- 11Gudala K, Kanukula R, Bansal D. Reduced risk of Parkinson’s disease in users of calcium channel blockers: a meta-analysis. Int J Chronic Dis 2015; 2015: 1–7.
10.1155/2015/697404 Google Scholar
- 12Bai S, Song Y, Huang X, et al. Statin use and the risk of Parkinson’s disease: an updated meta-analysis. PLoS One 2016; 11: e0152564.
- 13Becker C, Jick SS, Meier CR. NSAID use and risk of Parkinson disease: a population-based case–control study. Eur J Neurol 2011; 18: 1336–42.
- 14Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74: 995–1002.
- 15Alonso A, Rodríguez LAG, Logroscino G, et al. Gout and risk of Parkinson disease: a prospective study. Neurology 2007; 69: 1696–700.
- 16Ungprasert P, Srivali N, Thongprayoon C. Gout is not associated with a lower risk of Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2015; 21: 1238–42.
- 17Gasser T. Genetics of Parkinson’s disease. Ann Neurol 1998; 44: S53–57.
- 18Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol 2013; 47: 495–508.
- 19Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40.
- 20Hsu LJ, Sagara Y, Arroyo A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157: 401–10.
- 21Snyder H, Mensah K, Theisler C, et al. Aggregated and monomeric α-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 2003; 278: 11753–9.
- 22Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007; 27: 9220–32.
- 23Alim MA, Ma Q-L, Takeda K, et al. Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J Alzheimers Dis 2004; 6: 435–42; discussion 443–449.
- 24Scott DA, Tabarean I, Tang Y, et al. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 2010; 30: 8083–95.
- 25Marsden CD. Parkinson’s disease. Lancet 1990; 335: 948–9.
- 26Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211.
- 27Brundin P, Ma J, Kordower JH. How strong is the evidence that Parkinson’s disease is a prion disorder? Curr Opin Neurol 2016; 29: 459–66.
- 28Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease – the gut–brain axis and environmental factors. Nat Rev Neurol 2015; 11: 625.
- 29Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 2016; 167: 1469–1480.e12.
- 30Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276: 2045–7.
- 31Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis 2018; 109: 249–57.
- 32Chiba-Falek O, Lopez GJ, Nussbaum RL. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 2006; 21: 1703–8.
- 33Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989; 333: 1269.
- 34Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 2004; 304: 1158–60.
- 35Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605–8.
- 36Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256–9.
- 37Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515–7.
- 38Gan-Or Z, Dion PA, Rouleau GA. Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy 2015; 11: 1443–57.
- 39Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann Neurol 2002; 51: 296–301.
- 40Yue Z, Yang XW. Dangerous duet: LRRK2 and [alpha]-synuclein jam at CMA. Nat Neurosci 2013; 16: 375–7.
- 41Dehay B, Ramirez A, Martinez-Vicente M, et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci 2012; 109: 9611–6.
- 42Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38: 1184–91.
- 43Balestrino R, Schapira AHV. Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist 2018; 24: 540–59.
- 44Quadri M, Mandemakers W, Grochowska MM, et al. LRP10 genetic variants in familial Parkinson’s disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurol 2018; 17: 597–608.
- 45Williams ET, Chen X, Moore DJ. VPS35, the retromer complex and Parkinson’s disease. J Park Dis 2017; 7: 219–33.
- 46Calì T, Ottolini D, Brini M. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson’s disease. BioFactors Oxf Engl 2011; 37: 228–40.
- 47Spielman LJ, Gibson DL, Klegeris A. Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases. Neurochem Int 2018; 120: 149–63.
- 48Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 2013; 20: 16–34.
- 49Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DAT ATOP cohort. Neurology 1990; 40: 1529–34.
- 50Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale: comparison with the Unified Parkinson’s Disease Rating Scale. Mov Disord 2013; 28: 668–70.
- 51Fereshtehnejad S-M, Postuma RB. Subtypes of Parkinson’s disease: what do they tell us about disease progression? Curr Neurol Neurosci Rep 2017; 17: 34.
- 52Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017; 18: 435–50.
- 53Martinez-Martin P. Nonmotor symptoms and health-related quality of life in early Parkinson’s disease. Mov Disord 2014; 29: 166–8.
- 54Balestrino R, Martinez-Martin P. Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease. J Neurol Sci 2017; 373: 173–8.
- 55Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012; 27: 617–26.
- 56Postuma RB, Berg D. Prodromal Parkinson’s disease: the decade past, the decade to come. Mov Disord 2019. https://doi.org/10.1002/mds.27670.
- 57Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2019; 34: 1464–70.
- 58Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30: 1591–601.
- 59Brigo F, Erro R, Marangi A, et al. Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014; 20: 808–14.
- 60Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 2018; 33: 75–87.
- 61Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat Disord 2007; 13: 67–76.
- 62Stamelou M, Bhatia KP. Atypical parkinsonism: diagnosis and treatment. Neurol Clin 2015; 33: 39–56.
- 63Deutschländer AB, Ross OA, Dickson DW, et al. Atypical parkinsonian syndromes: a general neurologist’s perspective. Eur J Neurol 2017; 25: 41–58.
- 64Walker Z, Possin KL, Boeve BF, et al. Lewy body dementias. Lancet Lond Engl 2015; 386: 1683–97.
- 65Baizabal-Carvallo JF, Jankovic J. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol 2016; 12: 175.
- 66Poujois A, Woimant F. Challenges in the diagnosis of Wilson disease. Ann Transl Med 2019; 7: S67.
- 67Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primer 2015; 1: 15005.
- 68Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting Huntingtin expression in patients with Huntington’s disease. N Engl J Med 2019; 380: 2307–16.
- 69de la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012; 78: 696–701.
- 70King AE, Mintz J, Royall DR. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord 2011; 26: 1218–24.
- 71Shafieesabet A, Fereshtehnejad S-M, Shafieesabet A, et al. Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord 2017; 42: 1–11.
- 72Fox SH, Katzenschlager R, Lim S-Y, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011; 26: S2–41.
- 73Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord 2015; 30: 90–102.
- 74Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677–87.
- 75Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 2013; 28: 1064–71.
- 76Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology 2016; 86: S13–24.
- 77Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Curr Med Res Opin 2011; 27: 907–19.
- 78LeWitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov Disord 2014; 29: 75–82.
- 79Verhagen Metman L, Stover N, Chen C, et al. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson’s disease. Mov Disord 2015; 30: 1222–8.
- 80Blandini F, Armentero M-T. Dopamine receptor agonists for Parkinson’s disease. Expert Opin Investig Drugs 2014; 23: 387–410.
- 81Grosset KA, Malek N, Morgan F, et al. Inhaled dry powder apomorphine (VR040) for ‘off’ periods in Parkinson’s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand 2013; 128: 166–71.
- 82Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord 2016; 31: 1366–72.
- 83Robakis D, Fahn S. Defining the role of the monoamine oxidase-B inhibitors for Parkinson’s disease. CNS Drugs 2015; 29: 433–41.
- 84Schapira AHV, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 2017; 74: 216–24.
- 85Grégoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 2013; 19: 508–14.
- 86Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs 2015; 75: 157–74.
- 87Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015; 86: 767–73.
- 88Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012; 78: 1096–9.
- 89Crosby NJ, Deane KHO, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database Syst Rev 2003: CD003467.
- 90Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983–95.
- 91Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord 2017; 32: 1701–09.
- 92Stocchi F, Rascol O, Hauser RA, et al. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology 2017; 88: 2198–206.
- 93Charvin D, Medori R, Hauser RA, et al. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 2018; 17: 804–22.
- 94Lyons KE, Pahwa R, Hermanowicz N, et al. Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin. Expert Rev Clin Pharmacol 2019; 1–11.
- 95Chiken S, Nambu A. Mechanism of deep brain stimulation. Neuroscientist 2016; 22: 313–22.
- 96Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006; 355: 896–908.
- 97Defer G-L, Widner H, Marie R-M, et al. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 1999; 14: 572–584.
- 98Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 2013; 368: 610–22.
- 99Ishihara LS, Cheesbrough A, Brayne C, et al. Estimated life expectancy of Parkinson’s patients compared with the UK population. J Neurol Neurosurg Psychiatry 2007; 78: 1304–9.
- 100Xu J, Gong DD, Man CF, et al. Parkinson’s disease and risk of mortality: meta-analysis and systematic review. Acta Neurol Scand 2014; 129: 71–9.
- 101Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938–42.
- 102Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993; 43: 2227–9.
- 103 NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 2015; 14: 795–803.
- 104 Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561–6.
- 105Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69–73.
- 106 Parkinson Study Group QE3 Investigators, Beal MF, Oakes D et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 2014; 71: 543–52.
- 107 Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol. 1996; 39: 37–45.
- 108 Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 2015; 313: 584–93.
- 109Whone A, Luz M, Boca M, et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain 2019; 142: 512–25.
- 110Simuni T. A phase 3 study of isradipine as a disease-modifying agent in patients with early Parkinson’s disease (STEADY-PD III): final study results.2019.
- 111Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 1664–75.
- 112Martin-Bastida A, Ward RJ, Newbould R, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep 2017; 7: 1398.
- 113Bergström A-L, Kallunki P, Fog K. Development of passive immunotherapies for synucleinopathies. Mov Disord 2016; 31: 203–13.
- 114Moors TE, Hoozemans JJM, Ingrassia A, et al. Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease. Mol Neurodegener 2017; 12: https://doi.org/10.1186/s13024-017-0154-3.
- 115Pignataro D, Sucunza D, Rico AJ, et al. Gene therapy approaches in the non-human primate model of Parkinson’s disease. J Neural Transm Vienna Austria 1996; 2018: 575–89.
- 116McCormack AL, Mak SK, Henderson JM, et al. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One 2010; 5: e12122.
- 117Lindvall O, Rehncrona S, Gustavii B, et al. Fetal dopamine-rich mesencephalic grafts in Parkinson’s disease. Lancet Lond Engl 1988; 2: 1483–4.
- 118Madrazo I, León V, Torres C, et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson’s disease. N Engl J Med 1988; 318: 51.
- 119Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 1995; 332: 1118–24.
- 120Yasuhara T, Kameda M, Sasaki T, et al. Cell therapy for Parkinson’s disease. Cell Transplant 2017; 26: 1551–9.
- 121Studer L. Strategies for bringing stem cell-derived dopamine neurons to the clinic – the NYSTEM trial. Prog Brain Res 2017; 230: 191–212.